[go: up one dir, main page]

TN2013000393A1 - Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase - Google Patents

Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Info

Publication number
TN2013000393A1
TN2013000393A1 TNP2013000393A TN2013000393A TN2013000393A1 TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1 TN P2013000393 A TNP2013000393 A TN P2013000393A TN 2013000393 A TN2013000393 A TN 2013000393A TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1
Authority
TN
Tunisia
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
inhibitors
derivatives
Prior art date
Application number
TNP2013000393A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2013000393A1 publication Critical patent/TN2013000393A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention propose un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables associés; dans laquelle G représente (II) ou (III); R1, R2 et R3 sont tels que décrite ici; leurs compositions pharmaceutiques associées; et leur utilisation associée dans le traitement de maladies, états ou troubles modulés par l'inhibition d'une (d') enzyme (s) acétyl-CoA carboxylase chez un animal.
TNP2013000393A 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase TN2013000393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
TN2013000393A1 true TN2013000393A1 (fr) 2015-01-20

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000393A TN2013000393A1 (fr) 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Country Status (42)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN103492388A (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PH (1) PH12013501941A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53156B (en) * 2009-11-10 2014-06-30 Pfizer Inc. N1-PYRAZOLOSPIROKETONES AS ACETYL-COA CARBOXYLASE INHIBITORS
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
KR102243637B1 (ko) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 진통 화합물
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
HK1221411A1 (zh) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制劑和其用途
KR20160042089A (ko) * 2013-09-12 2016-04-18 화이자 인코포레이티드 심상성 여드름 치료용 아세틸-CoA 카복실라아제 억제제의 용도
EP3059225A4 (fr) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Nouveau dérivé d'alkylène
CN108947867A (zh) * 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
EP3114107B1 (fr) * 2014-03-07 2020-07-22 Recurium IP Holdings, LLC Dérivés de propellane et synthèse
CA2892342C (fr) 2014-05-22 2016-11-01 Sylvain-Paul Morency Outil et methode de depalletisation de couche
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
RU2759916C2 (ru) * 2015-12-31 2021-11-18 Цзянсу Тасли Дии Фармасьютикал Ко., Лтд. Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
DK3713942T3 (da) * 2017-11-21 2023-04-03 Pfizer Krystallinsk 2-amino-2-(hydroxymethyl)propan-1,3-diol-salt af 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazol-5,4'-piperidin]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoesyre
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN118271307A (zh) * 2022-12-30 2024-07-02 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024213044A1 (fr) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Dérivés de cycles fusionnés azacyclo-carbonyle et leur utilisation
WO2025036472A1 (fr) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Inhibiteur de prmt5 mta-coopératif spirocyclique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
CA2439152C (fr) 2001-02-28 2008-06-17 Merck & Co., Inc. Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine
ES2246481T3 (es) 2002-02-27 2006-02-16 Pfizer Products Inc. Inhibidores de la acc.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (fr) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Derive spiro, procede de production et antioxydant
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
DE602005015699D1 (de) 2004-05-12 2009-09-10 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
CN1950374A (zh) 2004-05-25 2007-04-18 辉瑞产品公司 四氮杂苯并[e]甘菊环衍生物及其类似物
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
NZ564591A (en) 2005-07-19 2010-01-29 Merck & Co Inc Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
CA2617042A1 (fr) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Compose spiro-cyclique
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007122482A1 (fr) 2006-04-20 2007-11-01 Pfizer Products Inc. Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase
ATE552262T1 (de) 2006-11-29 2012-04-15 Pfizer Prod Inc Spiroketone als inhibitoren von acetyl-coa- carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) * 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8114871B2 (en) 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
CA2724774C (fr) 2008-05-28 2013-06-25 Pfizer Inc. Inhibiteurs de la pyrazolospirocetone acetl-coa carboxylase
WO2010002010A1 (fr) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Nouveaux acides spirochromanone carboxyliques
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
EP2318370A1 (fr) 2008-07-29 2011-05-11 Pfizer Inc. Hétéroaryles fluorés
PT2334687E (pt) 2008-08-28 2012-04-13 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
MY151246A (en) 2009-03-11 2014-04-30 Pfizer Benzofuranyl derivatives
EP2406230A1 (fr) 2009-03-11 2012-01-18 Pfizer Inc. Indazole amides substitués
WO2010106457A2 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
WO2010128414A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs du gpr119
CN102459222B (zh) 2009-06-05 2014-06-04 辉瑞大药厂 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
US20120225900A1 (en) * 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
RS53156B (en) * 2009-11-10 2014-06-30 Pfizer Inc. N1-PYRAZOLOSPIROKETONES AS ACETYL-COA CARBOXYLASE INHIBITORS
ES2602111T3 (es) * 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona

Also Published As

Publication number Publication date
PT2699576E (pt) 2016-03-09
EA022375B1 (ru) 2015-12-30
DOP2013000243A (es) 2013-12-31
ECSP13013038A (es) 2014-01-31
US20150112068A1 (en) 2015-04-23
CN106117205A (zh) 2016-11-16
JP5657174B2 (ja) 2015-01-21
SI2699576T1 (sl) 2016-02-29
KR101567659B1 (ko) 2015-11-09
DK2699576T3 (en) 2016-02-15
EP2699576A1 (fr) 2014-02-26
TW201305162A (zh) 2013-02-01
SG194142A1 (en) 2013-11-29
EP2699576B1 (fr) 2015-12-09
AP2013007129A0 (en) 2013-09-30
AP3499A (en) 2015-12-31
TWI464171B (zh) 2014-12-11
CO6801757A2 (es) 2013-11-29
CA2831380A1 (fr) 2012-10-26
CR20130464A (es) 2013-10-16
US20150336958A1 (en) 2015-11-26
CN106117205B (zh) 2018-09-21
US20140323730A1 (en) 2014-10-30
NZ616156A (en) 2014-08-29
CU20130126A7 (es) 2014-01-29
IL228949A0 (en) 2013-12-31
AU2012245996A1 (en) 2013-10-03
ME02312B (me) 2016-06-20
HUE028602T2 (hu) 2016-12-28
JP2014515755A (ja) 2014-07-03
GT201300258A (es) 2015-06-02
UA107753C2 (xx) 2015-02-10
GEP20166474B (en) 2016-05-10
PH12013501941A1 (en) 2021-06-23
MA35061B1 (fr) 2014-04-03
CY1117122T1 (el) 2017-04-05
MY162167A (en) 2017-05-31
MX348860B (es) 2017-06-30
IL228949A (en) 2016-11-30
AU2012245996B2 (en) 2016-09-01
CN103492388A (zh) 2014-01-01
NI201300111A (es) 2014-02-12
ES2561452T3 (es) 2016-02-26
KR20140015511A (ko) 2014-02-06
RS54526B1 (en) 2016-06-30
PL2699576T3 (pl) 2016-05-31
CL2013002794A1 (es) 2013-12-27
UY34027A (es) 2013-04-05
HRP20151397T1 (hr) 2016-01-15
PE20141187A1 (es) 2014-09-18
CA2831380C (fr) 2016-04-05
MX2013012313A (es) 2014-01-31
US8802688B2 (en) 2014-08-12
US20120270893A1 (en) 2012-10-25
AR086198A1 (es) 2013-11-27
CU24164B1 (es) 2016-03-31
EA201391288A1 (ru) 2014-04-30
WO2012143813A1 (fr) 2012-10-26

Similar Documents

Publication Publication Date Title
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA38138A1 (fr) Dérivés inédits de quinolone
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse